All-grade toxicity | ≥G3 toxicity | |||
Univariate | Multivariable | Univariate | Multivariable | |
Age category | ||||
<65 years | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
65–74 years | 1.14 (0.73 to 1.76) | 1.27 (0.79 to 2.03) | 0.825 (0.47 to 1.45) | 0.96 (0.51 to 1.81) |
≥75 years | 0.88 (0.54 to 1.42) | 1.15 (0.70 to 1.91) | 0.53 (0.26 to 1.07) | 0.73 (0.33 to 1.61) |
Primary site | ||||
Melanoma | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
NSCLC | 0.79 (0.51 to 1.24) | 0.95 (0.59 to 1.53) | 0.50 (0.26 to 0.96) | 0.79 (0.38 to 1.62) |
RCC | 1.02 (0.60 to 1.74) | 1.50 (0.86 to 2.61) | 0.41 (0.18 to 0.95) | 0.90 (0.36 to 2.22) |
Treatment type | ||||
PD-1 inhibitor | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) | 1.00 (ref) |
Ipilimumab+nivolumab | 4.72 (1.36 to 16.39) | 5.24 (1.48 to 18.50) | 17.94 (6.71 to 47.91) | 16.41 (5.88 to 45.84) |
Ipilimumab | 8.17 (3.18 to 20.96) | 8.93 (3.43 to 23.29) | 7.73 (4.08 to 14.65) | 7.02 (3.53 to 13.96) |
OR with 95% CI for toxicity using logistic regression.
NSCLC, non-small cell lung cancer; RCC, renal cell carcinoma.